{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:03:56Z","timestamp":1785409436709,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"DOI":"10.7759\/cureus.113641","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:12:52Z","timestamp":1785406372000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses"],"prefix":"10.7759","author":[{"given":"David","family":"Ramzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Isshak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noma","family":"Shri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proggya","family":"Paromita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tashifa","family":"Nazmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez","family":"Shamoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.11.007","article-title":"Systematic review finds overlapping reviews were not mentioned in every other overview","volume":"67","author":"Pieper D","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014, 67:368-75. 10.1016\/j.jclinepi.2013.11.007","journal-title":"J Clin Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates M","year":"2022","unstructured":"Gates M, Gates A, Pieper D, et al.. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022, 378:e070849. 10.1136\/bmj-2022-070849","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto A","year":"2024","unstructured":"Saglietto A, Falasconi G, Penela D, et al.. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Clin Invest. 2024, 54:e14292. 10.1111\/eci.14292","journal-title":"Eur J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103067","article-title":"Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis","volume":"18","author":"Zhang HD","year":"2024","unstructured":"Zhang HD, Ding L, Liu K, et al.. Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024, 18:103067. 10.1016\/j.dsx.2024.103067","journal-title":"Diabetes Metab Syndr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1554795","article-title":"Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Wu R","year":"2025","unstructured":"Wu R, Xing B, Huang Y, Zhou Z, Sun B, Yu L, Wang H. Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025, 16:1554795. 10.3389\/fendo.2025.1554795","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.442","article-title":"Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Costa G","year":"2024","unstructured":"Costa G, Resende B, Cunha G, et al.. Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2024, 45:10.1093\/eurheartj\/ehae666.442","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156463","article-title":"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials","volume":"175","author":"Karakasis P","year":"2026","unstructured":"Karakasis P, Vlachos K, Antoniadis AP, Siontis KC, Patoulias D, Fragakis N, Mantzoros CS. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026, 175:156463. 10.1016\/j.metabol.2025.156463","journal-title":"Metabolism"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf257","article-title":"Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta-regression analysis of randomized controlled trials","author":"Cesaro A","year":"2025","unstructured":"Cesaro A, Pastori D, Acerbo V, et al.. Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta-regression analysis of randomized controlled trials. Eur J Prev Cardiol. 2025, zwaf257. 10.1093\/eurjpc\/zwaf257","journal-title":"Eur J Prev Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03124-y","article-title":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","volume":"30","author":"Wu R","year":"2025","unstructured":"Wu R, Xing B, Zhou Z, Yu L, Wang H. Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Eur J Med Res. 2025, 30:835. 10.1186\/s40001-025-03124-y","journal-title":"Eur J Med Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/pace.70262","article-title":"Effect of GLP-1 receptor agonists on post-ablation atrial fibrillation recurrence: a meta-analysis","author":"Shubietah A","year":"2026","unstructured":"Shubietah A, Elgendy MS, Awashra A, et al.. Effect of GLP-1 receptor agonists on post-ablation atrial fibrillation recurrence: a meta-analysis. Pacing Clin Electrophysiol. 2026, 10.1111\/pace.70262","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-025-02233-2","article-title":"GLP-1 receptor agonist therapy is associated with reduced atrial fibrillation recurrence after catheter ablation: a meta-analysis","volume":"69","author":"Kilic ME","year":"2026","unstructured":"Kilic ME, Turan OE, Yilancioglu RY, Ozcan EE. GLP-1 receptor agonist therapy is associated with reduced atrial fibrillation recurrence after catheter ablation: a meta-analysis. J Interv Card Electrophysiol. 2026, 69:321-3. 10.1007\/s10840-025-02233-2","journal-title":"J Interv Card Electrophysiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2026.05.048","article-title":"Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: a focused time-to-event meta-analysis","author":"Abomohsen M","year":"2026","unstructured":"Abomohsen M, Mohamed AE, Almakadma AH, Kholeif Z, Elshahat A, Ibrahim R, Syed A. Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: a focused time-to-event meta-analysis. Heart Rhythm. 2026, S1547-5271(26)02415-X. 10.1016\/j.hrthm.2026.05.048","journal-title":"Heart Rhythm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512637-glucagon-like-peptide-1-receptor-agonists-semaglutide-and-atrial-fibrillation-an-umbrella-review-with-methodological-appraisal-of-overlapping-meta-analyses","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:12:53Z","timestamp":1785406373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512637-glucagon-like-peptide-1-receptor-agonists-semaglutide-and-atrial-fibrillation-an-umbrella-review-with-methodological-appraisal-of-overlapping-meta-analyses"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.113641","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}